http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Suzuki, Ginga,Shimizu, Satoshi,Torii, Mana,Tokue, Ai,Ying, Guo,Yoshinari, Masao,Hoshi, Noriyuki,Kimoto, Katsuhiko,Miura, Hiromi,Hayakawa, Tohru,Ohkubo, Chikahiro The Korean Academy of Prosthodonitics 2020 The Journal of Advanced Prosthodontics Vol.12 No.6
PURPOSE. This study evaluated the availability of multi-directionally forged (MDF) titanium (Ti) as a component of removable partial dentures (RPDs). MDF-Ti remarkably improved the mechanical properties of RPDs due to its ultrafine-grained structure. MATERIALS AND METHODS. The wear resistance, plaque adhesion, and machinability of MDF-Ti were tested. As controls, commercially pure (CP) titanium was used for wear, plaque adhesion, and machinability tests. For wear resistance, the volume losses of the titanium teeth before and after wear tests were evaluated. Plaque adhesion was evaluated by the assay of Streptococcus mutans. In the machinability test, samples were cut and ground by a steel fissure bur and carborundum (SiC) point. An unpaired t-test was employed for the analysis of the significant differences between MDF-Ti and the control in the results for each test. RESULTS. Wear resistance and plaque adherence of MDF-Ti similar to those of CP-Ti (P>.05) were indicated. MDF-Ti exhibited significantly larger volume loss than CP-Ti in all conditions except 100/30,000 g/rpm in machinability tests (P<.05). CONCLUSION. Although the wear resistance and plaque adherence of MDF-Ti were comparable to those of controls, MDF-Ti showed better machinability than did CP-Ti. MDF-Ti could be used as a framework material for RPDs.
Kenichi Harano,Akihiro Hirakawa,Takayuki Kato,Keisuke Suzuki,Sachiko Watanabe,Noriyuki Katsumata 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.2
Objective: To assess the use of colony-stimulating factors (CSFs) in patients with ovarian cancer who receive adjuvant paclitaxel and carboplatin chemotherapy in clinical practice and to assess whether the frequency of CSF use differs among hospitals in Japan. Methods: CSF use in patients with ovarian cancer who received first-line paclitaxel and carboplatin was analyzed retrospectively using data from the Japanese hospitalization payment system. Results: A total of 1,050 patients at 104 hospitals were identified. The median age was 60 years (range, 22 to 88 years). Of these, 163 patients (15.5%) were diagnosed with neutropenia and 134 patients (12.8%) received CSFs. Among the patients who received CSFs, 125 (93%) received them for the treatment of neutropenia without fever and 1 received them for febrile neutropenia. In total, CSFs were administered for 272 cycles of chemotherapy. Among them, CSFs were used as treatment for neutropenia without fever in 259 cycles (95%), as prophylaxis (primary or secondary) in 12 cycles (4%), and as treatment for febrile neutropenia in 1 cycle. Among hospitals, a median of 4.0% of patients received CSFs with an interquartile range of 25% (Q1, 0%; Q3, 25%). A logistic random effects model showed that the variation in the proportion of patients receiving CSFs among the 104 hospitals was 2.0 (p<0.001), suggesting that the use of CSFs varied across hospitals. Conclusion: Most patients received CSFs for neutropenia without fever. Standardized and evidence-based use of CSFs is critically required among hospitals in Japan.
Satoko Iwasawa,Tazuru Tsuboi,Makiko Nakano,Aya Hirata,Noriyuki Yoshioka,Satoko Suzuki,Shigeru Tanaka,Kazuyuki Omae 한국대기환경학회 2019 Asian Journal of Atmospheric Environment (AJAE) Vol.13 No.2
The island of Miyakejima in Japan is subject to ongoing emissions of volcanic gases, including high concentrations of sulfur dioxide (SO2). Annual health checkups on the island, therefore, include the examination of respiratory system parameters. Here, we aimed to investigate the relationship between SO2 exposure and fractional exhaled nitric oxide (FeNO) concentration among children who received health checkups from 2008 to 2014. The subjects were 83 and 31 second-year junior high school students aged 13-14 years who resided on Miyakejima island and an SO2-free reference island, respectively. SO2 concentration in the air was measured at 6 fixed-point monitoring stations. FeNO was examined according to the American Thoracic Society guideline and European Respiratory Society recommendations for standardized procedures. Average concentrations of SO2 on Miyakejima over a period of 3 months prior to each health checkup from 2008 to 2014 were 22.2, 20.6, 8.9, 10.5, 10.7, 4.4 and 8.0 ppb, respectively. Among the Miyakejima students, geometric mean (GM) FeNO concentrations measured at each health checkup from 2008 to 2014 were 28.2, 18.2, 23.6, 35.5, 36.9, 28.1, and 32.1 ppb. The GM FeNO concentration measured from all Miyakejima students across the study period was 28.3 ppb. No clear dose-response relationship was observed. The GM FeNO concentration among the students from the reference island was 27.7 ppb in 2017. No significant difference was observed between the two populations, even when the data was stratified by sex and sensitivity. There was no clear significant difference in GM of FeNO concentration between Miyakejima and control students, when the average concentration of SO2 over a period of 3 months was 22 ppb or less.
( Tadakazu Hisamatsu ),( Hyo Jong Kim ),( Satoshi Motoya ),( Yasuo Suzuki ),( Yoshifumi Ohnishi ),( Noriyuki Fujii ),( Nobuko Matsushima ),( Richuan Zheng ),( Colleen W. Marano ) 대한장연구학회 2021 Intestinal Research Vol.19 No.4
Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with mod-erate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data from East-Asian patients included in the UNIFI program (NCT02407236). UNIFI consisted of two double-blind, placebo-controlled trials: an 8-week induction study and a 44-week randomized withdrawal maintenance study. Results: Of 133 East-Asian patients (Japanese: 107, Korean: 26) who underwent randomization, 131 completed induction study and 111 entered maintenance study. In the main-tenance study, 78 patients were randomized. Patients who received UST 130 mg and UST 6 mg/kg showed numerically higher clinical remission at week 8 in the induction study (5/44 [11.4%] and 5/45 [11.1%], respectively) compared with those who re-ceived placebo (0/44, 0%). The proportion of patients achieved clinical remission at week 44 was numerically higher in the UST 90 mg q12w group (10/21, 47.6%), but similar in the UST 90 mg q8w group (5/26, 19.2%) compared to placebo (7/31, 22.6%). Serious adverse events were reported in 1 patient in UST 130 mg group, but no patient in UST 6 mg/kg group through week 8 in the induction study, and 1 patient in UST 90 mg q12w group and 5 patients in the UST 90 mg q8w group in the maintenance study. No deaths were reported in East-Asian patients throughout the study. Conclusions: UST induction and maintenance treatments were effective in East-Asian patients with moderate to severe UC; the efficacy and safety profiles were consistent with the overall population. (Intest Res 2021;19:386-397)